-
1.发明申请ALGORITHMS FOR OUTCOME PREDICTION IN PATIENTS WITH NODE-POSITIVE CHEMOTHERAPY-TREATED BREAST CANCER 审中-公开患有结直肠癌治疗乳腺癌的患者的预后预测方法公开(公告)号：US20110166838A1
公开(公告)日：2011-07-07
申请号：US12999522
申请日：2009-06-16
IPC分类号： G06F7/60
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G16B20/00 , G16B25/00 , G16B40/00
摘要： The invention relates to methods for predicting an outcome of cancer in a patient suffering from cancer, said patient having been previously diagnosed as node positive and treated with cytotoxic chemotherapy, said method comprising determining in a biological sample from said patient an expression level of a plurality of genes selected from the group consisting of ACTG1, CAl2, CALM2, CCND1, CHPT1, CLEC2B, CTSB, CXCL13, DCN, DHRS2, EIF4B, ERBB2, ESR1, FBXO28, GABRP, GAPDH, H2AFZ, IGFBP3, IGHG1, IGKC, KCTD3, KIAA0101, KRT17, MLPH, MMP1, NAT1, NEK2, NR2F2, OAZ1, PCNA, PDLIM5, PGR, PPIA, PRC1, RACGAP1, RPL37A, SOX4, TOP2A, UBE2C and VEGF; ABCB1, ABCG2, ADAM15, AKR1C1, AKR1C3, AKT1, BANF1, BCL2, BIRC5, BRMS1, CASP10, CCNE2, CENPJ, CHPT1, EGFR, CTTN, ERBB3, ERBB4, FBLN1, FIP1L1, FLT1, FLT4, FNTA, GATA3, GSTP1, Herstatin, IGF1R, IGHM, KDR, KIT, CKRT5, SLC39A6, MAPK3, MAPT, MKI67, MMP7, MTA1, FRAP1, MUC1, MYC, NCOA3, NFIB, OLFM1, TP53, PCNA, PI3K, PPERLD1, RAB31, RAD54B, RAF1, SCUBE2, STAU, TINF2, TMSL8, VGLL1, TRA@, TUBA1, TUBB, TUBB2A.
摘要翻译： 本发明涉及用于预测患有癌症的患者的癌症结果的方法，所述患者先前被诊断为淋巴结阳性并用细胞毒性化疗治疗，所述方法包括在来自所述患者的生物样品中确定多个表达水平 选自ACTG1，CA2，CALM2，CCND1，CHPT1，CLEC2B，CTSB，CXCL13，DCN，DHRS2，EIF4B，ERBB2，ESR1，FBXO28，GABRP，GAPDH，H2AFZ，IGFBP3，IGHG1，IGKC，KCTD3， KIAA0101，KRT17，MLPH，MMP1，NAT1，NEK2，NR2F2，OAZ1，PCNA，PDLIM5，PGR，PPIA，PRC1，RACGAP1，RPL37A，SOX4，TOP2A，UBE2C和VEGF; ABCB1，ABCG2，ADAM15，AKR1C1，AKR1C3，AKT1，BANF1，BCL2，BIRC5，BRMS1，CASP10，CCNE2，CENPJ，CHPT1，EGFR，CTTN，ERBB3，ERBB4，FBLN1，FIP1L1，FLT1，FLT4，FNTA，GATA3，GSTP1， Herbatin，IGF1R，IGHM，KDR，KIT，CKRT5，SLC39A6，MAPK3，MAPT，MKI67，MMP7，MTA1，FRAP1，MUC1，MYC，NCOA3，NFIB，OLFM1，TP53，PCNA，PI3K，PPERLD1，RAB31，RAD54B，RAF1， SCUBE2，STAU，TINF2，TMSL8，VGLL1，TRA @，TUBA1，TUBB，TUBB2A。
-
公开(公告)号：US20130065786A1
公开(公告)日：2013-03-14
申请号：US13638360
申请日：2011-03-29
申请人： Mareike Dartmann , Inke Sabine Feder , Mathias Gehrmann , Guido Hennig , Karsten Weber , Christian Von Törne , Ralf Kronenwett , Christoph Petry
发明人： Mareike Dartmann , Inke Sabine Feder , Mathias Gehrmann , Guido Hennig , Karsten Weber , Christian Von Törne , Ralf Kronenwett , Christoph Petry
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates to methods, kits and systems for the prognosis of the disease outcome of breast cancer, said method comprising: (a) determining in a tumor sample from said patient the RNA expression levels of at least 2 of the following 9 genes: UBE2C, BIRC5, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP (b) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is indicative of a prognosis of said patient; and kits and systems for performing said method.
摘要翻译： 本发明涉及用于乳腺癌疾病预后的方法，试剂盒和系统，所述方法包括：（a）在所述患者的肿瘤样品中测定以下9个基因中至少2个的RNA表达水平： UBE2C，BIRC5，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP（b）在数学上组合所述组的基因的表达水平值，其在肿瘤样品中测定以产生组合评分，其中所述组合 评分表示所述患者的预后; 以及用于执行所述方法的套件和系统。
-
3.发明申请公开(公告)号：US20140228241A1
公开(公告)日：2014-08-14
申请号：US14235168
申请日：2012-07-30
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q1/6809 , C12Q2600/106 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： A method for predicting a response to and/or benefit of chemotherapy, including neoadjuvant chemotherapy, in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer, said method comprising the steps of: (a) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, RACGAP1, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP, indicative of a response to chemotherapy for a tumor, or (b) determining in a tumor sample from said patient the RNA expression levels of the following 8 genes: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST, and MGP; indicative of a response to chemotherapy for a tumor (c) mathematically combining expression level values for the genes of the said set which values were determined in the tumor sample to yield a combined score, wherein said combined score is predicting said response and/or benefit of chemotherapy.
摘要翻译： 一种在患有或有发生复发性肿瘤疾病，特别是乳腺癌风险的患者中预测化疗（包括新辅助化疗）的反应和/或益处的方法，所述方法包括以下步骤：（a）在 来自所述患者的肿瘤样品包括以下8个基因：UBE2C，RACGAP1，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP的RNA表达水平，其指示对肿瘤的化学疗法的反应，或（b）在肿瘤中测定 来自所述患者的样品来自以下8个基因的RNA表达水平：UBE2C，BIRC5，DHCR7，STC2，AZGP1，RBBP8，IL6ST和MGP; 指示对肿瘤的化学疗法的反应（c）在数学上组合所述组的基因的表达水平值，所述基因在肿瘤样品中测定以产生组合评分，其中所述组合评分预测所述应答和/或益处 的化疗。
-
公开(公告)号：US09932639B2
公开(公告)日：2018-04-03
申请号：US12745668
申请日：2008-11-06
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The present invention is related to a method for analyzing a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of three genes of interest, said genes being correlated with the Estrogen receptor (ESR) status in the sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c); and treating based on said outcome.
-
公开(公告)号：US20110118129A1
公开(公告)日：2011-05-19
申请号：US12745668
申请日：2008-11-06
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c). Moreover, the invention concerns nucleic acid molecules usefuls as primers and probes for detecting the expression of Her2-neu/ErbB2, MLHP and MMP7, respectively.
摘要翻译： 本发明涉及一种用于预测患有或具有发展为肿瘤疾病的风险的患者的临床反应朝向至少一种给定治疗方式的方法，所述方法包括以下步骤：a）从所述的方法获得生物样品 患者; b）在非蛋白质基础上确定至少一种目标基因的表达水平，所述基因与所述样品中的雌激素受体（ESR）状态相关，c）比较在（b）中确定的表达水平的模式 ）具有一个或几个表达水平的参考模式; 以及d）从步骤（c）中的比较结果预测所述患者中所述给定治疗模式的治疗成功。 此外，本发明涉及分别用作检测Her2-neu / ErbB2，MLHP和MMP7表达的引物和探针的核酸分子。
-
公开(公告)号：US20180251854A1
公开(公告)日：2018-09-06
申请号：US15913563
申请日：2018-03-06
IPC分类号： C12Q1/6886
CPC分类号： C12Q1/6886 , C12Q2600/112 , C12Q2600/118 , C12Q2600/158
摘要： The present invention is related to a method for predicting a clinical response of a patient suffering from or at risk of developing a neoplastic disease towards at least one given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining, on a non protein basis, the expression level of at least one gene of interest, said gene being correlated with the Estrogen receptor (ESR) status in the said sample, c) comparing the pattern of expression levels determined in (b) with one or several reference pattern(s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient from the outcome of the comparison in step (c).
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.03 秒)